Vertex Pharmaceuticals

NASDAQ: VRTX
$214.35
+$1.67 (+0.8%)
Closing price May 13, 2021
Here are five notable health care laggard stocks that appear to have plenty of upside potential. Most of them are dividend payers too.
Wednesday's top analyst upgrades and downgrades included Applied Materials, Caterpillar, Costco Wholesale, JPMorgan, Spotify, Vertex Pharmaceutical, Vornado Realty Trust and Whiting Petroleum.
A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth...
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Monday's top analyst upgrades and downgrades included Apple, BP, CrowdStrike, Delta Air Lines, Moody's, NuStar Energy, PPL, Salesforce.com, Slack Technologies and Wells Fargo.
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic...
Thursday's top analyst upgrades and downgrades included Alkermes, Amazon.com, Citigroup, eBay, Fastly, Groupon, Lyft, Netflix, ONEOK, Roku, Uber Technologies and Zoom Video Communications.
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
These five high-conviction health care stock picks from the analysts at Jefferies all make sense for investors looking to gain exposure to a sector that should continue to do well the rest of 2020...
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The August 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Jefferies analysts have named 10 companies they think have a solid chance of posting second-quarter results that exceed current Wall Street consensus estimates.